Stockreport

Pharvaris Presents Data at the Bradykinin Symposium 2024

Pharvaris N.V. - Ordinary Shares  (PHVS) 
PDF ZUG, Switzerland, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor ant [Read more]